Julio Rosenstock, Marisa Vico, Li Wei, Afshin Salsali, James F List. Diabetes Care 2012
Times Cited: 271
Times Cited: 271
Times Cited
Times Co-cited
Similarity
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
56
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
51
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List. Lancet 2010
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List. Lancet 2010
49
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
K Strojek, K H Yoon, V Hruba, M Elze, A M Langkilde, S Parikh. Diabetes Obes Metab 2011
K Strojek, K H Yoon, V Hruba, M Elze, A M Langkilde, S Parikh. Diabetes Obes Metab 2011
47
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Ann Intern Med 2012
John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Ann Intern Med 2012
37
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
35
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
35
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
34
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
32
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
30
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
29
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
29
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
C S Kovacs, V Seshiah, R Swallow, R Jones, H Rattunde, H J Woerle, U C Broedl. Diabetes Obes Metab 2014
C S Kovacs, V Seshiah, R Swallow, R Jones, H Rattunde, H J Woerle, U C Broedl. Diabetes Obes Metab 2014
27
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
27
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
24
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
24
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
23
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh. J Am Geriatr Soc 2014
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh. J Am Geriatr Soc 2014
23
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
22
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
22
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
22
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
22
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
C J Bailey, N Iqbal, C T'joen, J F List. Diabetes Obes Metab 2012
C J Bailey, N Iqbal, C T'joen, J F List. Diabetes Obes Metab 2012
22
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
22
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
John P H Wilding, Paul Norwood, Caroline T'joen, Arnaud Bastien, James F List, Fred T Fiedorek. Diabetes Care 2009
John P H Wilding, Paul Norwood, Caroline T'joen, Arnaud Bastien, James F List, Fred T Fiedorek. Diabetes Care 2009
22
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
K Kaku, S Inoue, O Matsuoka, A Kiyosue, H Azuma, N Hayashi, T Tokudome, A M Langkilde, S Parikh. Diabetes Obes Metab 2013
K Kaku, S Inoue, O Matsuoka, A Kiyosue, H Azuma, N Hayashi, T Tokudome, A M Langkilde, S Parikh. Diabetes Obes Metab 2013
21
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
21
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
20
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J Woerle, Uli C Broedl. Diabetes Care 2014
Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J Woerle, Uli C Broedl. Diabetes Care 2014
20
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
20
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
William T Cefalu, Lawrence A Leiter, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh. Diabetes Care 2015
William T Cefalu, Lawrence A Leiter, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh. Diabetes Care 2015
21
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
19
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
18
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba,[...]. Diabetes Care 2015
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba,[...]. Diabetes Care 2015
18
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
K Kaku, A Kiyosue, S Inoue, N Ueda, T Tokudome, J Yang, A M Langkilde. Diabetes Obes Metab 2014
K Kaku, A Kiyosue, S Inoue, N Ueda, T Tokudome, J Yang, A M Langkilde. Diabetes Obes Metab 2014
25
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
18
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
19
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Michael A Weber, Traci A Mansfield, Valerie A Cain, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Lancet Diabetes Endocrinol 2016
Michael A Weber, Traci A Mansfield, Valerie A Cain, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Lancet Diabetes Endocrinol 2016
17
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
J Rosenstock, A Jelaska, C Zeller, G Kim, U C Broedl, H J Woerle. Diabetes Obes Metab 2015
J Rosenstock, A Jelaska, C Zeller, G Kim, U C Broedl, H J Woerle. Diabetes Obes Metab 2015
17
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Stephan Matthaei, Keith Bowering, Katja Rohwedder, Anke Grohl, Shamik Parikh. Diabetes Care 2015
Stephan Matthaei, Keith Bowering, Katja Rohwedder, Anke Grohl, Shamik Parikh. Diabetes Care 2015
17
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
16
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
16
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg, Nayyar Iqbal. Diabetes Care 2015
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg, Nayyar Iqbal. Diabetes Care 2015
15
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
15
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
14
Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.
Krzysztof Strojek, Kun-Ho Yoon, Veronika Hruba, Jennifer Sugg, Anna Maria Langkilde, Shamik Parikh. Diabetes Ther 2014
Krzysztof Strojek, Kun-Ho Yoon, Veronika Hruba, Jennifer Sugg, Anna Maria Langkilde, Shamik Parikh. Diabetes Ther 2014
27
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
14
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
S Del Prato, M Nauck, S Durán-Garcia, L Maffei, K Rohwedder, A Theuerkauf, S Parikh. Diabetes Obes Metab 2015
S Del Prato, M Nauck, S Durán-Garcia, L Maffei, K Rohwedder, A Theuerkauf, S Parikh. Diabetes Obes Metab 2015
14
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
14
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.